Molecular basis for the antiandrogen withdrawal syndrome

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 3-12

  Miyamoto, Hiroshi ^a   Rahman, Mujib M ^a   Chang, Chawnshang ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Androgen receptor; Androgen receptor coregulator; Combined androgen blockade; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; REGULATOR PROTEIN;

CANCER GROWTH; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; WITHDRAWAL SYNDROME; BLOOD; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 1842471816     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10757     Document Type: Review

References (69)

1. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. 1999. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19:5143-5154.
2. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. 1999. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and androgen-independent human xenograft models. Cancer Res 59:4761-4764.
3. Akakura K, Akimoto S, Ohki T, Shimazaki J. 1995. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45:700-704.
4. Bissada NK, Kaczmarek AT. 1995. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 153: 1944-1945.
5. Chang C, Kokontis J, Liao S. 1988. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326.
6. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee H-J, Wang C, Mizokami A. 1995. Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr 5:97-125.
7. 5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci USA 96:11173-11177.
8. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
9. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
10. Dawson NA, McLeod DG. 1995. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946-1947.
11. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
12. Dorai T, Cao Y-C, Dorai B, Buttyan R, Katz AE. 2001. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47:293-303.
13. Fujimoto N, Yeh S, Kang H-Y, Inui S, Chang H-C, Mizokami A, Chang C. 1999. Cloning and characterization of androgen receptor coactivator ARA55 in human prostate. J Biol Chem 274:8316-8321.
14. Fujimoto N, Mizokami A, Harada S, Matsumoto T. 2001. Different expression of androgen receptor coactivators in human prostate. Urology 58:289-294.
15. Furuya Y, Akimonto S, Akakura K, Igarashi T, Murakami S, Shimazaki J, Ito H. 1998. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 60:28-32.
16. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. 1998. The androgen receptor gene mutations database. Nucleic Acids Res 26:234-238.
17. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724.
18. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
19. Kara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. 2003. Novel mutation of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153.
20. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: An overview. Endocr Rev 23:175-200.
21. Hellerstedt BA, Pienta KJ. 2002. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:23-47.
22. Huan SD, Gerridzen RG, Yau JC, Stewart DJ. 1997. Antiandrogen withdrawal syndrome with nilutamide. Urology 49:632-634.
23. Huggins C, Hodges CV. 1941. Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297.
24. Isaacs JT. 1999. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26:263-273.
25. Jemal A, Samuels A, Ghafoor A, Ward E, Thun MJ. 2003. Cancer statistics, 2003. CA Cancer J Clin 53:5-26.
26. Kelly WK, Scher HI. 1993. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 149:607-609.
27. Kelly WK, Slovin S, Scher HI. 1997. Steroid hormone withdrawal syndromes: Pathophysiology and clinical significance. Urol Clin North Am 24:421-431.
28. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. 2001. A combination therapy of domamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 86:5729-5736.
29. Kwiatkowski DJ. 1999. Functions of gelsolin: Motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 11:103-108.
30. Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, Chang C. 2002. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 62:6039-6044.
31. Lin H-K, Yeh S, Kang H-Y, Chang C. 2001. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205.
32. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TLJ, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
33. 2 in patients with hormone refractory prostate cancer. Clin Cancer Res 8: 2820-2827.
34. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastman J, Weigel NL, Lamb DJ. 2000. Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949.
35. McKenna NJ, Lanz RB, O'Malley BW. 1999. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 20:321-344.
36. Mitchell SH, Zhu W, Young CYF. 1999. Resveratrol inhibits expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59:5892-5895.
37. Miyamoto H, Chang C. 2000. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 7:32-34.
38. 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95:11083-11088.
39. Miyamoto H, Yeh S, Wilding G, Chang C. 1998b. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379-7384.
40. Miyamoto H, Rahman M, Takatera H, Kang H-Y, Yeh S, Chang H-C, Nishimura K, Fujimoto N, Chang C. 2002. A dominant-negative mutant androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 277:4609-4617.
41. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 2003. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci USA 100:4440-4444.
42. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. 2002. HER-2 profiling and targeting in prostate carcinoma: A phase II trial of trastuzumab alone and with paclitaxel. Cancer 94:980-986.
43. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597-7609.
44. Nishimura K, Ting H-J, Harada Y, Tokizane T, Nonomura N, Kang H-Y, Chang H-C, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C. 2003. Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. Cancer Res 63:4888-4894.
45. Paul R, Breul J. 2000. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: Incidence and clinical significance. Drug Safety 23:381-390.
46. Plonowski A, Schally AV, Nagy A, Sun BD, Szepeshazi K. 1999. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 59:1947-1953.
47. Rahman MM, Miyamoto H, Lardy H, Chang C. 2003a. Inactivation of androgen receptor coregulator, ARA55, leads to an inhibition of androgen receptor transactivation and the agonist activity of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 100:5124-5129.
48. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C. 2003b. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 278:19619-19626.
49. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG. 2001. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 49:797-811.
50. Russell PJ, Bennett S, Stricker P. 1998. Growth factor involvement in progression of prostate cancer. Clin Chem 44:705-723.
51. Scher HI, Zhang Z-F, Cohen L, Kelly WK. 1995. Hormonally relapsed prostatic cancer: Lessons from the flutamide withdrawal syndrome. Adv Urol 8:61-95.
52. Sella A, Flex D, Sulkes A, Baniel J. 1998. Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 52:1091-1093.
53. Shibanuma M, Mashimo J, Kuroki T, Nose K. 1994. Characterization of the TGFβ1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 269:26767-26774.
54. Small EJ, Carroll PR. 1994. Prostate-specific antigen decline after casodex withdrawal: Evidence for an anti-androgen withdrawal syndrome. Urology 43:408-410.
55. Small EJ, Srinivas S. 1895. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428-1434.
56. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WL, Shi Y. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99:5515-5520.
57. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. 1996. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 29:153-158.
58. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
59. Taplin M-E, Bubley GJ, Ko Y-J, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
60. Tilley WD, Buchanan G, Mickey TE, Bentel JM. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
61. Torchia J, Glass C, Rosenfeld MG. 1998. Coactivators and corepressors in the integration of transcriptional responses. Curr Opin Cell Biol 10:373-383.
62. Truica CI, Byers S, Gelmann EP. 2000. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713.
63. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
64. Voeller HJ, Truica CI, Gelmann EP. 1998. β-Catenin mutations in human prostate cancer. Cancer Res 58:2520-2523.
65. Wen Y, Hu MC-T, Makino K, Spohn B, Bartholomeusz G, Yan D-H, Hung M-C. 2000. Her-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
66. Wilding G, Chen M, Gelmann EP. 1989. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115.
67. Yeh S, Miyamoto H, Chang C. 1997. Hydroxyflutamide may not always be a pure antiandrogen. Lancet 349:852-853.
68. Yeh S, Kang H-Y, Miyamoto H, Nishimura K, Chang H-C, Ting H-J, Rahman M, Lin H-K, Fujimoto N, Hu Y-C, Mizokami A, Huang K-E, Chang C. 1999. Differential induction of androgen receptor transactivation by different androgen receptor coactivatos in human prostate cancer DU 145 cells. Endocrine 11:195-202.
69. Zhang Y, Ni J, Messing EM, Chang E, Yang C-R, Yeh S. 2002. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 99:7408-7413.